ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

Screening Guidelines: When Scientists Can’t Agree, What’s The Press To Do?

May 15, 1998

Eight Win ASCO Young Investigator Awards

August 22, 1986

ASCO, AACR Honor Scientists, Journalists At Annual Meetings

May 29, 1992

NCI Cooperative Group Clinical Trials Approved

February 26, 2010

Cancer Groups Urge FDA To Spell Out Standards For Data Collection In Time-To-Progression Trials.

November 7, 2008

In Brief: Univ. of New Mexico Looked Over As Possible Comprehensive Center; Missouri Asks Delay

November 26, 1976